Condition: Locoregional Recurrence · Hormone Receptor-positive Breast Cancer · HER2-negative Breast Cancer · Sponsor: Oana Danciu
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
This description comes directly from the study's public registry record.
Oana Danciu, MD · 312-996-1581 · ocdanciu@uic.edu
Amber Ryba · 317-634-5842 · aryba@hoosiercancer.org
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of Arizona | Phoenix, Arizona, United States | Recruiting |
| Georgetown University | Washington D.C., District of Columbia, United States | Recruiting |
| Orlando Health Cancer Institute | Orlando, Florida, United States | Active Not Recruiting |
| University of Illinois Cancer Center | Chicago, Illinois, United States | Recruiting |
| Parkview Research Center | Fort Wayne, Indiana, United States | Recruiting |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| University of Michigan Health System | Ann Arbor, Michigan, United States | Recruiting |
| University of Michigan Health-West | Wyoming, Michigan, United States | Terminated |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05467891